February 1, 2018

HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target

Clin Cancer Res. 2018 May 15;24(10):2395-2407. doi: 10.1158/1078-0432.CCR-17-1594. Epub 2018 Feb 1.

Fok JHL, Hedayat S, Zhang L, Aronson LI, Mirabella F, Pawlyn C, Bright MD, Wardell CP, Keats JJ, De Billy E, Rye CS, Chessum NEA, Jones K, Morgan GJ, Eccles SA, Workman P, Davies FE


Myeloma is a plasma cell malignancy characterized by the overproduction of immunoglobulin, and is therefore susceptible to therapies targeting protein homeostasis. We hypothesized that heat shock factor 1 (HSF1) was an attractive therapeutic target for myeloma due to its direct regulation of transcriptional programs implicated in both protein homeostasis and the oncogenic phenotype. Here, we interrogate HSF1 as a therapeutic target in myeloma using bioinformatic, genetic, and pharmacologic means.

Read more: https://www.ncbi.nlm.nih.gov/pubmed/29391353